Last reviewed · How we verify
LEVALBUTEROL HYDROCHLORIDE
At a glance
| Generic name | LEVALBUTEROL HYDROCHLORIDE |
|---|---|
| Modality | Small molecule |
| Phase | FDA-approved |
| First approval | 1999 |
Approved indications
Common side effects
- Palpitations
- Chest pain
- Tachycardia
- Headache
- Dizziness
- Tremor
- Nervousness
Serious adverse events
- Serious adverse events (unspecified)
- Clinically significant ECG changes
Key clinical trials
- Albuterol Versus Xopenex in Treatment of Acute Asthma in the Emergency Department (ED) (PHASE4)
- Nebulized Ketamine Plus Standard Care vs. Standard Care Alone in Moderate to Severe Asthma Exacerbations (PHASE2)
- Efficacy and Safety of Levalbuterol in Chronic Obstructive Pulmonary Disease (COPD) (PHASE3)
- A Pilot Study to Determine the Most Effective Dose of Arformoterol for Treating Acute Asthmatic Patients (PHASE4)
- Continuation of TRAVERSE- LTS12551 Evaluating Dupilumab Safety in Patients With Asthma (Long-Term Follow-Up) (PHASE3)
- A Comparison of Levalbuterol Plus Ipratropium With Levalbuterol Alone in the Treatment of Acute Asthma Exacerbation (NA)
- Evaluation of Dupilumab's Effects on Airway Inflammation in Patients With Asthma (PHASE2)
- Evaluation of Dupilumab in Children With Uncontrolled Asthma (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- LEVALBUTEROL HYDROCHLORIDE CI brief — competitive landscape report
- LEVALBUTEROL HYDROCHLORIDE updates RSS · CI watch RSS